Tesla Inc's stock jumped above $1,000 a share on Wednesday after Chief Executive Elon Musk told his staff it was time to bring the Tesla Semi commercial truck to "volume production." Musk on Wednesday tweeted "Yes" to a question on Twitter about whether the report of the leaked Semi truck production email was accurate. Tesla's shares rose about 6% to hit $1,000 on Wednesday after Reuters reported Musk's email, making the Silicon Valley company the second-most valuable automaker in the world, behind Japan's Toyota Motor Corp ....
Stock futures were mixed Wednesday morning as market participants awaited the Federal Reserve’s latest monetary policy decision and commentary later in the afternoon....
Hertz (HTZ) has announced that it has received a letter from the New York Stock Exchange (NYSE) revealing plans to delist Hertz’s common stock from the exchange. Shares in HTZ are down 12% in Wednesday’s pre-market trading.According to an SEC filing made by Hertz, NYSE Regulation reached its decision after Hertz disclosed on May 22, 2020 that it has commenced voluntary petitions for reorganization under chapter 11 of the Bankruptcy Code.Hertz says it has appealed the determination and has requested a hearing before the NYSE. “At this time, the common stock of the company will continue to be listed and trade on the NYSE pending resolution of such appeal” Hertz says.The company adds that there can be no assurance that the NYSE will grant its request for continued listing at the hearing and therefore “whether there will be equity value in the company’s common stock.”Despite an impressive rally over the last...
Tesla Inc's chief executive Elon Musk said that it is time to bring its Semi commercial truck to "volume production", as the U.S. electric vehicle maker ramps up vehicle production after a brief virus-related shutdown. "Production of the battery and powertrain will take place at Giga Nevada," Musk said in an email seen by Reuters....
Shares in Genmab A/S (GMAB) rose in pre-market trading after announcing a collaboration agreement with AbbVie (ABBV) to jointly develop and commercialize three of its early-stage investigational bispecific antibody product candidates.The stock advanced 5% to $30.32 in Wednesday’s pre-market trading. The two companies said that they will also collaborate on research to develop future differentiated antibody therapeutics for cancer.As part of the partnership they will develop Genmab’s next-generation bispecific antibody programs, epcoritamab (DuoBody-CD3xCD20), DuoHexaBody-CD37 and DuoBody-CD3x5T4.“Epcoritamab is a strong fit for our robust hematological oncology franchise”, said Michael Severino, Vice Chairman and President at AbbVie. “By combining the strengths of our two organizations, we can advance the treatment landscape for patients battling cancer.”Under the financial terms of the collaboration, AbbVie will pay Genmab $750 million in an upfront payment with the potential for Genmab to receive up to $3.15 billion in additional development, regulatory and sales milestone payments for all programs....
